The 6th Cytokine-Based Drug Development Summit (May 15-16 in Boston) returns as the only industry focused conference that ...
As a bonus, Bavarian Nordic also gets a priority review voucher from the FDA, awarded as an incentive to carry out drug development for a neglected tropical disease, that can be used to reduce the ...
Shares in the UK's IP Group slid today after it revealed that an arthritis drug in development at one of its portfolio ...
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...
Ono – which acquired rights to Romvimza when it bought Deciphera Pharma in a $2.4 billion deal that closed in 2023 – said ...
Recently hired employees of the FDA and CDC look set to be the latest federal employees to be affected by the sweeping job cuts implemented by the Trump administration on agencies overseen by the ...
This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...
Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...
The pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of the most recent trends and technologies. One important piece of the puzzle that ...
Over 6.3 million patients make up the NHS backlog for consultant-led elective care, which reached 7,573,212 in September 2024. Of the patients on the list, nearly 249,300 have been waiting for ...
Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs) on the Nasdaq, taking the number in the newly-filed queue to four since the start of the year.
Left to right: Quibim chief operating officer Alberto Valiente, CEO and co-founder Dr Ángel Alberich-Bayarri, and Javier Sáez, VP of finance and business intelligence. Artificial intelligence ...